Émilie Soularue1, Romain Cohen1, Christophe Tournigand2, Aziz Zaanan3, Christophe Louvet4, Jean-Baptiste Bachet5, Olivia Hentic6, Emmanuelle Samalin7, Benoist Chibaudel8, Aimery de Gramont9, Thierry André10. 1. Hôpital Saint-Antoine, 75012 Paris, France. 2. Hôpital Henri-Mondor, 94000 Créteil, France. 3. Hôpital européen George-Pompidou, 75015 Paris, France. 4. Institut mutualiste Montsouris, 75014 Paris, France. 5. Hôpital de la Pitié-Salpêtrière, 75013 Paris, France. 6. Hôpital Beaujon, 92110 Clichy, France. 7. Institut régional du cancer Montpellier - Val-d'Aurelle, 34000 Montpellier, France. 8. Institut hospitalier franco-britannique, 92300 Levallois-Perret, France; GERCOR-IRC (Groupe coopérateur multidisciplinaire en oncologie-Innovative Research Consortium), 151, rue du Faubourg-Saint-Antoine, 75011 Paris, France. 9. Institut hospitalier franco-britannique, 92300 Levallois-Perret, France. 10. Hôpital Saint-Antoine, 75012 Paris, France. Electronic address: thierry.andre@sat.aphp.fr.
Abstract
BACKGROUND: Trastuzumab with 5-fluorouracil (5-FU) and cisplatin offers prolonged survival in patients with HER2-overexpressing advanced gastric cancer (AGC) and advanced gastro-oesophageal junction cancer (AGOJ). Oxaliplatin in combination with intravenous 5-FU plus leucovorin (LV; modified [m]FOLFOX6) or capecitabine (XELOX) improves tolerability compared with 5-FU/cisplatin regimen. There are few data available on the efficacy and safety of trastuzumab-oxaliplatin-based chemotherapy in previously untreated HER2-positive AGC and AGOJ patients. METHODS: Clinical data were retrospectively analysed in patients receiving trastuzumab plus mFOLFOX6 or XELOX as first-line therapy between July 2009 and December 2012. Eligible patients had histologically proven AGC or AGOJ, HER2 overexpression, and no prior chemotherapy for metastatic disease. RESULTS: Thirty-four patients met the eligibility criteria. Median age was 63 years, 79% of patients had ECOG PS score of 0-1, and all had metastatic disease. Median duration of treatment was 7.5 months. Overall response rate was 41% (95% CI: 25-56). Median progression-free survival and overall survival were 9.0 months (95% CI: 5.6-12) and 17.3 months (95% CI: 13.5-32.3), respectively. Tolerability was acceptable. The most frequent grade 3-4 toxicities were neutropenia (8.8%) and neuropathy (17.6%). CONCLUSION: mFOLFOX6-trastuzumab combination is an efficient regimen with an acceptable safety profile for AGC and AGOJ patients. These results warrant further prospective study.
BACKGROUND:Trastuzumab with 5-fluorouracil (5-FU) and cisplatin offers prolonged survival in patients with HER2-overexpressing advanced gastric cancer (AGC) and advanced gastro-oesophageal junction cancer (AGOJ). Oxaliplatin in combination with intravenous 5-FU plus leucovorin (LV; modified [m]FOLFOX6) or capecitabine (XELOX) improves tolerability compared with 5-FU/cisplatin regimen. There are few data available on the efficacy and safety of trastuzumab-oxaliplatin-based chemotherapy in previously untreated HER2-positive AGC and AGOJ patients. METHODS: Clinical data were retrospectively analysed in patients receiving trastuzumab plus mFOLFOX6 or XELOX as first-line therapy between July 2009 and December 2012. Eligible patients had histologically proven AGC or AGOJ, HER2 overexpression, and no prior chemotherapy for metastatic disease. RESULTS: Thirty-four patients met the eligibility criteria. Median age was 63 years, 79% of patients had ECOG PS score of 0-1, and all had metastatic disease. Median duration of treatment was 7.5 months. Overall response rate was 41% (95% CI: 25-56). Median progression-free survival and overall survival were 9.0 months (95% CI: 5.6-12) and 17.3 months (95% CI: 13.5-32.3), respectively. Tolerability was acceptable. The most frequent grade 3-4 toxicities were neutropenia (8.8%) and neuropathy (17.6%). CONCLUSION:mFOLFOX6-trastuzumab combination is an efficient regimen with an acceptable safety profile for AGC and AGOJ patients. These results warrant further prospective study.
Authors: Karsten Kleo; Vladimir M Jovanovic; Alexander Arndold; Annika Lehmann; Hedwig Lammert; Erika Berg; Hannah Harloff; Christoph Treese; Michael Hummel; Severin Daum Journal: J Cancer Res Clin Oncol Date: 2022-03-05 Impact factor: 4.553
Authors: Sebastian Mondaca; Matthew Margolis; Francisco Sanchez-Vega; Philip Jonsson; Jamie C Riches; Geoffrey Y Ku; Jaclyn F Hechtman; Yaelle Tuvy; Michael F Berger; Manish A Shah; David P Kelsen; David H Ilson; Kenneth Yu; Zoe Goldberg; Andrew S Epstein; Avni Desai; Vincent Chung; Joanne F Chou; Marinela Capanu; David B Solit; Nikolaus Schultz; Yelena Y Janjigian Journal: Gastric Cancer Date: 2018-08-07 Impact factor: 7.370
Authors: Mustafa Gürbüz; Erman Akkuş; Abdullah Sakin; Semiha Urvay; Atike Gökçen Demiray; Süleyman Şahin; Teoman Şakalar; Cihan Erol; Mehmet Ali Nahit Şendur; Ahmet Bilgehan Şahin; Erdem Çubukçu; Deniz Can Güven; Saadettin Kılıçkap; Yakup Ergün; Doğan Uncu; Nazım Serdar Turhal; Necdet Üskent; Havva Yeşil Çınkır; Atakan Demir; Ramazan Acar; Nuri Karadurmuş; Sema Türker; Mustafa Altınbaş; Mert Karaoğlan; Filiz Çay Şenler Journal: J Gastrointest Cancer Date: 2021-02-04